Free tool
FAERS Monitor: Lonsurf
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207981 or its brand name (Lonsurf, Tipiracil Hydrochloride, Trifluridine). Reports on generic versions are filed under their own applications.
Reports
10,823
Serious
8,549
79% of reports
Hospitalization
2,990
Death reported
4,240
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death3,101
- disease progression1,795
- fatigue1,435
- nausea1,202
- diarrhoea1,040
- decreased appetite695
- vomiting649
- asthenia510
- white blood cell count decreased500
- anaemia375
- drug ineffective370
- neutropenia362
- constipation349
- weight decreased339
- dehydration334
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 57 |
| 2016 | 1,355 |
| 2017 | 1,424 |
| 2018 | 1,345 |
| 2019 | 944 |
| 2020 | 964 |
| 2021 | 971 |
| 2022 | 870 |
| 2023 | 1,042 |
| 2024 | 752 |
| 2025 | 639 |
| 2026 | 460 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,336 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease progressionSignal | 1,795 | 29.9 | 28.7 | 49,666 |
| white blood cell count decreasedSignal | 500 | 9.0 | 8.3 | 3,550 |
| deathSignal | 3,101 | 7.0 | 6.8 | 16,616 |
| decreased appetiteSignal | 695 | 5.8 | 5.4 | 2,798 |
| neutropeniaSignal | 362 | 5.2 | 4.7 | 1,223 |
| dehydrationSignal | 334 | 4.9 | 4.4 | 1,029 |
| anaemiaSignal | 375 | 3.8 | 3.5 | 786 |
| fatigueSignal | 1,435 | 3.6 | 3.4 | 2,772 |
| diarrhoeaSignal | 1,040 | 3.1 | 3.0 | 1,555 |
| constipationSignal | 349 | 3.1 | 2.8 | 503 |
| nauseaSignal | 1,202 | 3.0 | 2.8 | 1,610 |
| vomitingSignal | 649 | 2.7 | 2.5 | 699 |
| astheniaSignal | 510 | 2.6 | 2.4 | 526 |
| weight decreasedSignal | 339 | 2.4 | 2.1 | 268 |
| drug ineffective | 370 | 0.5 | 0.5 | 149 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.